CA Patent

CA3002493C — Methotrexate formulation

Assigned to Therakind Ltd · Expires 2023-11-28 · 2y expired

What this patent protects

A liquid pharmaceutical composition comprises methotrexate free acid and a buffer, wherein the pH of the composition is in the range of 6.5 to 8.2. Processes for preparation of the liquid pharmaceutical composition are also described. The liquid pharmaceutical composition is usef…

USPTO Abstract

A liquid pharmaceutical composition comprises methotrexate free acid and a buffer, wherein the pH of the composition is in the range of 6.5 to 8.2. Processes for preparation of the liquid pharmaceutical composition are also described. The liquid pharmaceutical composition is useful in therapy.

Drugs covered by this patent

chembl-chembl34259 (METHOTREXATE)

Patent Metadata

Patent number: CA3002493C
Jurisdiction: CA
Classification: —
Expires: 2023-11-28
Drug substance claim: No
Drug product claim: No
Assignee: Therakind Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.